leadf
logo-loader
viewMGC Pharmaceuticals Ltd
(
LSE:MXCOTC:MGCLFFRA:H5OASX:MXC
)

MGC Pharma takes final step towards emergency-use authorisation for its COVID-19 treatment in India

MGC Pharma Ltd co-founder and managing director Roby Zomer joined Proactive’s Stephen Gunnion with news that the company was granted approval by the Indian authorities to import its phytomedicine CimetrA into that country as a final step towards obtaining emergency-use authorisation for the treatment of patients with coronavirus (COVID-19).

Zomer telling Proactive that India has been acutely affected by the COVID-19 pandemic and MGC Pharma believes that CimetrA can make an important difference in treating the symptoms of COVID-19 and alleviating patient suffering.
 

Quick facts: MGC Pharmaceuticals Ltd

Follow
LSE:MXC

Price: 3.1 GBX

Market Cap: £73.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

MGC Pharmaceuticals: Continuous global breakthroughs as progress accelerates

Proactive Research Analyst Ed Stacey presents his analysis on MGC Pharmaceuticals (LON:MXC).  The company recently announced that it has received a UK import permit for CannEpil+, which is MGC’s cannabis-derived therapy for refractory epilepsy, to be used initially on a compassionate access...

1 week, 3 days ago

2 min read